Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CALT Calliditas Therapeutics

15.020
-0.146-0.96%
Close 10/03 16:00 ET
High
15.400
Open
15.400
Turnover
61.63K
Low
14.900
Pre Close
15.166
Volume
4.08K
Market Cap
444.27M
P/E(TTM)
Loss
52wk High
27.500
Shares
29.58M
P/E(Static)
Loss
52wk Low
12.550
Float Cap
354.24M
Bid/Ask %
0.00%
Historical High
38.000
Shs Float
23.58M
Volume Ratio
0.64
Historical Low
12.550
Dividend TTM
--
Div Yield TTM
--
P/B
6.64
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.02%
Amplitude
3.30%
Avg Price
15.124
Lot Size
1
Float Cap
354.24M
Bid/Ask %
0.00%
Historical High
38.000
Shs Float
23.58M
Volume Ratio
0.64
Historical Low
12.550
Dividend TTM
--
P/B
6.64
Dividend LFY
--
Turnover Ratio
0.02%
Amplitude
3.30%
Avg Price
15.124
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt ?ke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
CEO: Ms. Renee Aguiar-Lucander
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...